Heller Bridgette P 4

What Happened
Bridgette P. Heller, a director of Dexcom, sold 1,012 shares on February 12, 2026 at $68.01 per share, for proceeds of $68,826. The filing indicates the shares were disposed pursuant to a 10b5-1 trading plan adopted by Ms. Heller on August 14, 2025. This was a sale (not a purchase), which is commonly a routine disposition rather than a direct signal of changed sentiment.

Key Details

• Transaction date and price: 2026-02-12 — 1,012 shares sold at $68.01 each (total $68,826).
• Sale type/code: Open-market sale (reported as "S"); executed under a pre-established 10b5-1 plan (see footnote).
• Filing date: Form 4 filed 2026-02-17. (Filed within typical SEC reporting timeframe.)
• Shares owned after transaction: Not specified in the provided excerpt.
• Notable footnotes:
  • F1: 10b5-1 plan adopted Aug 14, 2025; the sale was made pursuant to that plan.
  • F2: The filing notes 5,046 unvested restricted stock units granted May 8, 2025 that vest by the earlier of the one-year anniversary of the grant or Dexcom’s 2026 Annual Meeting.

Context
Sales executed under 10b5-1 plans are pre-scheduled and often reflect planned diversification or liquidity needs; they are less informative about an insider’s current view of the company than new, unscheduled purchases. No options exercise, gift, or tax-withholding transaction was reported in this filing excerpt.